Biologikanebenwirkungen bei Psoriasis
Standard
Biologikanebenwirkungen bei Psoriasis. / Altenburg, A; Augustin, M; Zouboulis, C C.
in: HAUTARZT, Jahrgang 69, Nr. 4, 04.2018, S. 290-297.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biologikanebenwirkungen bei Psoriasis
AU - Altenburg, A
AU - Augustin, M
AU - Zouboulis, C C
PY - 2018/4
Y1 - 2018/4
N2 - Background. The introduction of biologics has revolutionized the treatment of moderate to severe plaque psoriasis. Due to the continuous expansion of biological therapies for psoriasis, it is particularly important to acknowledge efficacy and safety of the compounds not only in clinical trials but also in long-term registry-based observational studies. Aim. Typical side effects and significant risks of antipsoriatic biologic therapies considering psoriatic control groups are presented. Materials and methods. A selective literature search was conducted in PubMed and long-term safety studies of the psoriasis registries PsoBest, PSOLAR and BADBIR were evaluated. Results and discussion. To assess the long-term safety of biologics, the evaluation of the course of large patient cohorts in long-term registries is of particular medical importance. Newer biologic drugs seem to exhibit a better safety profile than older ones.
AB - Background. The introduction of biologics has revolutionized the treatment of moderate to severe plaque psoriasis. Due to the continuous expansion of biological therapies for psoriasis, it is particularly important to acknowledge efficacy and safety of the compounds not only in clinical trials but also in long-term registry-based observational studies. Aim. Typical side effects and significant risks of antipsoriatic biologic therapies considering psoriatic control groups are presented. Materials and methods. A selective literature search was conducted in PubMed and long-term safety studies of the psoriasis registries PsoBest, PSOLAR and BADBIR were evaluated. Results and discussion. To assess the long-term safety of biologics, the evaluation of the course of large patient cohorts in long-term registries is of particular medical importance. Newer biologic drugs seem to exhibit a better safety profile than older ones.
KW - English Abstract
KW - Journal Article
KW - Review
U2 - 10.1007/s00105-018-4156-z
DO - 10.1007/s00105-018-4156-z
M3 - SCORING: Review
C2 - 29568996
VL - 69
SP - 290
EP - 297
JO - HAUTARZT
JF - HAUTARZT
SN - 0017-8470
IS - 4
ER -
